Related Experiment Video
Updated: Dec 22, 2025
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy
Chhavi Gupta1, Akash Sali1, Binyun Ma2
1Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Background:
Prostate cancer is managed by surgery, androgen deprivation and cytotoxic chemotherapy. Targeted therapy is emerging as an important pillar in cancer therapeutics, however, efficacy in prostate cancer has been limited. Eph-ephrin is a novel pathway that is upregulated in prostate cancer and promotes the initiation and progression of cancer. The aim of this study was to determine the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma.
Methods:
A tissue microarray comprising of prostate adenocarcinoma of different grade groups was stained with a monoclonal anti-ephrinB2 antibody (Abcam, AB201512). The tumor and endothelial cells expressing the ephrinB2 positivity were noted. The statistical analysis was performed to determine the difference in expression based on grade groups and the TNM stage.
Results:
EphrinB2 was expressed in 40 out of 72 cases (55.5 %) of prostate adenocarcinoma and was predominantly negative in the normal prostatic tissue. There was no significant difference in the expression of ephrinB2 in various grade groups (p = 0.7) or stages (p = 0.6).
Conclusions:
EphrinB2 is expressed in a significant number of prostate adenocarcinoma regardless of grade and stage. Hence, there is a potential to target this molecule in the low-grade tumors with localized disease as well as high grade, high volume tumors with metastatic disease.
Insights
EphrinB2 is present in over half of prostate adenocarcinomas, offering a potential therapeutic target. This expression is consistent across various tumor grades and stages, indicating broad applicability for targeted therapy in prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer treatment relies on surgery, hormone therapy, and chemotherapy.
- Targeted therapies show limited efficacy in prostate cancer.
- The Eph-Ephrin pathway is implicated in prostate cancer initiation and progression.
Purpose of the Study:
- To investigate the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma.
- To correlate ephrinB2 expression with tumor grade and TNM stage.
Main Methods:
- Tissue microarray of prostate adenocarcinoma samples.
- Immunohistochemical staining using a monoclonal anti-ephrinB2 antibody.
- Statistical analysis of expression based on grade groups and TNM stage.
Main Results:
- EphrinB2 was expressed in 55.5% of prostate adenocarcinoma cases.
- Expression was predominantly negative in normal prostatic tissue.
- No significant difference in ephrinB2 expression was found across different grade groups or TNM stages.
Conclusions:
- EphrinB2 is significantly expressed in prostate adenocarcinoma, irrespective of grade and stage.
- EphrinB2 represents a potential therapeutic target for both localized and metastatic prostate cancer.
- Targeting ephrinB2 may be beneficial in low-grade, localized, and high-grade, metastatic prostate cancers.
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...